指南与共识头颈外科

头颈癌患者对NCCN治疗后监测指南的依从性

Adherence with National Comprehensive Cancer Network posttreatment surveillance guidelines in patients with head and neck cancer.
指南 / 共识 · Head Neck · 2019-09-09

本研究以NCCN头颈癌指南评估221例患者监测依从性,发现50.2%依从,距治疗中心距离是唯一显著关联因素;依从性与总生存无显著关联(aHR=0.68,95%CI 0.43-1.09),但治疗完成后5-10年依从是独立生存预测因素(aHR=0.24,95%CI 0.09-0.61)。

要点

  • 约半数头颈癌患者未完全遵循NCCN监测指南。
  • 距治疗中心距离是监测依从性的唯一显著关联因素。
  • 治疗完成后5-10年,依从监测与更好生存独立相关。

核心结论

  • 头颈癌患者监测依从性对改善生存重要,尤其在长期随访中。

研究设计与样本

  • 回顾性研究,依据NCCN头颈癌指南评估221例头颈癌患者的监测依从性。
  • 采用逻辑回归和Cox比例风险模型分析依从性预测因素及总生存。

主要发现

  • 221例患者中110例(50.2%)依从监测。
  • 距治疗中心距离是依从性的唯一显著关联因素。
  • 多因素调整后依从性与总生存无显著关联(aHR=0.68,95%CI 0.43-1.09)。
  • 治疗完成后5-10年,依从性是生存的独立预测因素(aHR=0.24,95%CI 0.09-0.61)。

临床怎么用

  • 应关注距治疗中心较远患者的监测依从性。
  • 长期随访中强调依从监测以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surveillance in head and neck cancer (HNC) is essential to detect recurrent or new lesions and to optimize function. This study describes drivers of surveillance adherence in patients with HNC and its effect on prognosis. METHODS: Adherence with surveillance of HNC patients was determined using the National Comprehensive Cancer Network HNC guidelines. Logistic regression and Cox proportional hazards models were used to determine predictors of adherence and overall survival (OS). RESULTS: Results showed that 110 of 221 patients (50.2%) were adherent with surveillance. Distance from the treatment center was the only significant association. Adherence was not associated with OS following multivariate adjustment (adjusted hazard ratio [aHR] = 0.68, 95% confidence interval [CI] = 0.43-1.09). However, 5-10 years after treatment completion, adherence was an independent predictor of survival (aHR = 0.24, 95% CI = 0.09-0.61). CONCLUSION: Adherence with surveillance is important in improving survival in patients with HNC, especially in the long term.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Tam S, Nurgalieva Z, Weber RS, et al. Adherence with National Comprehensive Cancer Network posttreatment surveillance guidelines in patients with head and neck cancer. Head Neck. 2019. PMID: 31497912. doi:10.1002/hed.25936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。